<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-169701" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>C3 Glomerulopathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ayehu </surname>
            <given-names>Gashu</given-names>
          </name>
          <aff>Glomerular Center at Northwell Health and Donald and Barbara Zucker School of Medicine, NY</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Atari</surname>
            <given-names>Mohammad</given-names>
          </name>
          <aff>University of Mississippi Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hassanein</surname>
            <given-names>Mohamed</given-names>
          </name>
          <aff>University of Mississippi Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jhaveri</surname>
            <given-names>Kenar</given-names>
          </name>
          <aff>Glomerular Center at Northwell Health, Northwell Health, Donald and Barbara Zucker School of Medicine, Great Neck, NY</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gashu Ayehu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohammad Atari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohamed Hassanein declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kenar Jhaveri declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>11</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-169701.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>A consensus report in 2013 defined the term C3 glomerulopathy (C3G) to describe a group of glomerular disorders resulting from dysregulation of the complement system's alternative pathway.<xref ref-type="bibr" rid="article-169701.r1">[1]</xref>&#x000a0;This condition is characterized by the dominant deposition of C3 in the glomerulus without or with scant immunoglobulin deposition. C3G encompasses 2 major subtypes&#x02014;C3 glomerulonephritis (C3GN) and dense deposit disease (DDD)&#x02014;based on different patterns of C3 deposition on electron microscopy. C3GN comprises about 66% of cases and DDD about 33%. Previously, these disease processes were often classified as types of membranoproliferative disease.<xref ref-type="bibr" rid="article-169701.r2">[2]</xref> Clinical manifestations of both can include features of both nephritic and nephrotic syndromes.</p>
        <p>C3 glomerulopathy involves intricate complement system dysregulation. A solid understanding of the alternative complement pathway, how it differs from other complement-mediated diseases, and the role of genetic mutations or autoantibodies is essential for accurate diagnosis and management. The diagnosis of C3 glomerulopathy requires the use of advanced diagnostic tools, such as studies for autoantibodies to complement system components, genetic identification of essential complement proteins and regulatory proteins, and histologic analysis of kidney tissue.</p>
      </sec>
      <sec id="article-169701.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>Dysregulation of the alternative pathway can result from&#x000a0;genetic mutations or the production of autoantibodies.</p>
        <p>
<bold>Genetic Mutations</bold>
</p>
        <p>Mutations involved are in the genes that encode for C3, complement factor B, factor H, factor I, and complement factor H-related protein 5.<xref ref-type="bibr" rid="article-169701.r2">[2]</xref><xref ref-type="bibr" rid="article-169701.r3">[3]</xref>&#x000a0;About 25% of patients have detectable genetic mutations in these complement-related genes. However, due to the complexity of the complement system, few patients have relatives with the same disease.<xref ref-type="bibr" rid="article-169701.r4">[4]</xref><xref ref-type="bibr" rid="article-169701.r5">[5]</xref>&#x000a0;Among patients diagnosed with familial C3G, C3GN is more common than DDD.<xref ref-type="bibr" rid="article-169701.r4">[4]</xref></p>
        <p>
<bold>Autoantibodies</bold>
</p>
        <p>Autoantibodies to various complement proteins stabilize the target complement proteins, increase their half-life, and prolong their activity.<xref ref-type="bibr" rid="article-169701.r2">[2]</xref>&#x000a0;C3 nephritic factor (CNeF) is the most common autoantibody known to cause C3G and does so by stabilizing C3 convertase (C3bBb), making it less susceptible to degradation by complement factor H and extending its biological activity.<xref ref-type="bibr" rid="article-169701.r6">[6]</xref> Other autoantibodies include C5 nephritic factor against C5 convertase and autoantibodies against factor H and factor B. Paraproteinemias are thought to act as autoantibodies to C3 convertase or other regulating factors.<xref ref-type="bibr" rid="article-169701.r7">[7]</xref></p>
      </sec>
      <sec id="article-169701.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>C3G is a rare condition; its incidence and prevalence are challenging to assess accurately. The best available information from registry data suggests that incidence and prevalence are approximately 1 to 3 cases per million and 5 cases per million, respectively, in the United States.<xref ref-type="bibr" rid="article-169701.r3">[3]</xref> Patients with DDD tend to be younger than those with C3GN. Previously, DDD was considered a disease of children and young adults, but some series have also shown a prevalence in patients older than 60.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/keywords/cmeuserviewpopupwithquestions/171229?Return=%2FKeywords%2FIndex#link_30692664">[2]</ext-link><xref ref-type="bibr" rid="article-169701.r8">[8]</xref> Both C3GN and DDD are most common in White patients and least common in Black patients.<xref ref-type="bibr" rid="article-169701.r9">[9]</xref></p>
      </sec>
      <sec id="article-169701.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The complement system involves over 50 proteins and regulatory factors and can be cell-bound or soluble in the bloodstream. C3 is a common plasma protein in concentrations of up to 1.2 mg/mL, while factor H is the most common regulatory factor. Dysregulation of the alternative pathway underlies the development of C3G. Unlike the classical and lectin pathways of the complement system, the alternative pathway is constitutively active at a basal level, resulting from spontaneous hydrolysis of C3.</p>
        <p>The basal activation of C3 is normally regulated by essential complement regulatory proteins, including factor H, factor H-related proteins, factor I, and membrane cofactor proteins. If left unchecked, activated C3 amplifies activation of the alternative pathway in a positive feedback loop, recruits inflammatory cells, and leads to membrane attack complex formation. Deposition of complement proteins in the glomerulus and tissue injury follows, leading to the histologic and clinical manifestations of C3G.<xref ref-type="bibr" rid="article-169701.r4">[4]</xref>&#x000a0;Dysregulation of the alternative pathway can result from genetic mutations, acquired autoantibody-related processes, or direct activation of the pathway via a systemic process, such as systemic lupus erythematosus, monoclonal gammopathy of undetermined significance, or monoclonal gammopathy of renal significance.<xref ref-type="bibr" rid="article-169701.r7">[7]</xref> In the genetic form, gain-of-function mutations in complement-related proteins lead to overactivation of the alternative pathway.<xref ref-type="bibr" rid="article-169701.r2">[2]</xref></p>
      </sec>
      <sec id="article-169701.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The diagnosis of C3G rests on biopsy findings characterized by glomerulonephritis with dominant C3 staining on immunofluorescence, as defined in the consensus report in 2013.<xref ref-type="bibr" rid="article-169701.r1">[1]</xref> The report defined &#x0201c;dominant&#x0201d; as staining for C3 at least 2 orders of magnitude greater than any other immune reactants (ie, immunoglobulins, C1q, C4).<xref ref-type="bibr" rid="article-169701.r1">[1]</xref><xref ref-type="bibr" rid="article-169701.r10">[10]</xref> Light microscopy findings vary from normal morphology in rare cases to mesangial proliferative, membranoproliferative, and endocapillary proliferative with or without crescents.</p>
        <p>Electron microscopy is essential to differentiate between DDD and C3GN. In DDD, electron microscopy reveals highly electron-dense deposits that appear sausage-like and are found within the lamina densa of the glomerular basement membrane, the mesangium, Bowman capsule, and the tubular basement membrane. These deposits are sometimes described as "ribbon-like."<xref ref-type="bibr" rid="article-169701.r4">[4]</xref><xref ref-type="bibr" rid="article-169701.r8">[8]</xref> In some cases, the deposits may involve the subendothelial and subepithelial regions of the glomerular basement membrane.</p>
        <p>In C3GN, by contrast, deposits seen during electron microscopy are less dense, less organized, and are primarily in the mesangium and capillary walls.<xref ref-type="bibr" rid="article-169701.r7">[7]</xref><xref ref-type="bibr" rid="article-169701.r11">[11]</xref> In both DDD and C3GN, large subepithelial humps like those seen in infection-related glomerulonephritis (IRGN) may be found. In C3G, these subepithelial humps are composed of alternative complement pathway elements, while in infection-related glomerulonephritis, they are composed of immunoglobulins.<xref ref-type="bibr" rid="article-169701.r2">[2]</xref><xref ref-type="bibr" rid="article-169701.r8">[8]</xref></p>
      </sec>
      <sec id="article-169701.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The presentation of C3G varies from asymptomatic hematuria and proteinuria to symptoms of both nephritic and nephrotic syndrome. Microscopic hematuria, proteinuria, and hypertension are the most common presenting findings&#x000a0;in patients with C3G.<xref ref-type="bibr" rid="article-169701.r3">[3]</xref>&#x000a0;Nephrotic syndrome is seen more frequently in C3GN than in DDD, while acute kidney injury is infrequent in C3GN and even rarer in DDD. In children and young adults, the diagnosis of C3G is often preceded by an upper respiratory infection, and older patients are more likely to have paraproteinemia.<xref ref-type="bibr" rid="article-169701.r4">[4]</xref> Patients with monoclonal immunoglobulin G-related C3G are at a median age of 60 at diagnosis, compared to a median age of 28 in those with non-monoclonal immunoglobulin G-related C3G.<xref ref-type="bibr" rid="article-169701.r7">[7]</xref></p>
        <p>Atypical hemolytic uremic syndrome with thrombotic microangiopathy lesions on histopathological examination is seen concurrently in fewer than 10% of patients with C3G.<xref ref-type="bibr" rid="article-169701.r12">[12]</xref> Extrarenal manifestations, rare in C3G, are more common in concurrent C3G/atypical hemolytic uremic syndrome disease and include cutaneous and gastrointestinal symptoms. Patients with concurrent disease present with more severe acute kidney injury, although less severe than in atypical hemolytic uremic syndrome alone.<xref ref-type="bibr" rid="article-169701.r12">[12]</xref></p>
      </sec>
      <sec id="article-169701.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>C3G is a histopathologic diagnosis and requires a kidney biopsy. Please refer to the <bold>Histopathology</bold> section for a discussion of diagnostic findings.&#x000a0;A kidney biopsy diagnostic of C3G&#x000a0;should prompt a comprehensive investigation of the complement system's alternative pathway. While the availability of studies will be institution-dependent, the 2021 Kidney Disease Improving Global Outcomes guidelines recommend the following studies:</p>
        <list list-type="bullet">
          <list-item>
            <p>Functional complement studies: hemolytic complement, CH50; alternative pathway, AP50; fumarate hydratase function</p>
          </list-item>
          <list-item>
            <p>Complement quantification: C3; complement component 4; factor I; factor H; factor B; properdin</p>
          </list-item>
          <list-item>
            <p>Complement activation: C3d; membrane attack complex; Bb</p>
          </list-item>
          <list-item>
            <p>Autoantibodies: anti-factor H; anti-factor B; nephritic factors</p>
          </list-item>
        </list>
        <p>In patients who are found to have C3 nephritic factor, measurement of its capacity to stabilize C3 convertase should be attempted when possible.<xref ref-type="bibr" rid="article-169701.r3">[3]</xref>&#x000a0;Notably, only 50% to 70% of patients with C3G have low C3 levels, so normal levels do not rule out this disease.<xref ref-type="bibr" rid="article-169701.r5">[5]</xref>&#x000a0;For patients older than 50, an evaluation for dysproteinemia should be performed, including quantification of urine and serum free light chains and protein electrophoresis immunofixation, to establish the presence or absence of conditions such as multiple myeloma, Waldenstr&#x000f6;m macroglobulinemia, amyloidosis or monoclonal gammopathy of renal significance. Paraproteins may act as a nephritic factor or an H autoantibody factor. A bone marrow biopsy may be warranted if other abnormalities are found.<xref ref-type="bibr" rid="article-169701.r2">[2]</xref> Genetic testing for variants of complement genes, including <italic toggle="yes">C3</italic>, <italic toggle="yes">CFB</italic>, <italic toggle="yes">CFH</italic>, <italic toggle="yes">CFHR5,</italic> and <italic toggle="yes">CFI</italic>, should be considered when possible but remains challenging as these tests may not be readily available outside specialized laboratories.<xref ref-type="bibr" rid="article-169701.r3">[3]</xref></p>
      </sec>
      <sec id="article-169701.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>C3G treatment largely depends on disease severity at presentation after ruling out infection-related glomerulonephritis and in the absence of an underlying pathologic B-cell or plasma cell clone. Based on the degree of proteinuria and kidney function at diagnosis, C3G is classified into the following 3 categories:</p>
        <list list-type="bullet">
          <list-item>
            <p>Mild disease (proteinuria &#x0003c;1 g/day and stable/normal kidney function)</p>
          </list-item>
          <list-item>
            <p>Moderate-severe disease (proteinuria &#x0003e;1 g/day or worsening renal function over a few months)</p>
          </list-item>
          <list-item>
            <p>C3G with a rapidly progressive glomerulonephritis presentation (crescent formation on kidney biopsy and rapid deterioration of kidney function) <xref ref-type="bibr" rid="article-169701.r13">[13]</xref></p>
          </list-item>
        </list>
        <p>Supportive care, such as what is usually implemented for the management of patients with chronic kidney disease, is indicated for all the patients diagnosed with C3G regardless of disease severity and includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension management</p>
          </list-item>
          <list-item>
            <p>Salt restriction</p>
          </list-item>
          <list-item>
            <p>Anti-proteinuric therapies like angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and sodium-glucose cotransporter 2 inhibitors</p>
          </list-item>
          <list-item>
            <p>Lipid-lowering therapy&#x000a0;for hyperlipidemia</p>
          </list-item>
          <list-item>
            <p>Diuretics for edema, if needed</p>
          </list-item>
        </list>
        <p>No single&#x000a0;therapeutic regimen&#x000a0;is universally effective for C3G. Patients with mild C3G can be treated with only supportive care and monitored over time. Immunosuppressive therapies are recommended for patients with moderate-severe C3G. If monoclonal gammopathy is present, treatment of the underlying disorder is warranted. Per 2021 Kidney Disease Improving Global Outcomes guidelines, in the absence of monoclonal gammopathy, a mycophenolate mofetil and steroid combination regimen is the first-line recommended treatment in the management of patients with moderate-to-severe C3G and is superior to other immunosuppressive agents in terms of remission induction and kidney survival.<xref ref-type="bibr" rid="article-169701.r13">[13]</xref> Doses of mycophenolate mofetil (MMF) range from 750 to 1500 mg per day, with a mean of 1000 mg daily.<xref ref-type="bibr" rid="article-169701.r14">[14]</xref> Pulse steroids can be considered for proteinuria in excess of 2 grams per day.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopup/171042#link_30692664">[2]</ext-link>&#x000a0;Eculizumab, a complement C5 inhibitor, is indicated in patients resistant to MMF and steroids or with findings concerning rapidly progressive disease.<xref ref-type="bibr" rid="article-169701.r15">[15]</xref> Patients with a rapidly progressive glomerulonephritis presentation can be treated with a regimen composed of high-dose steroids in addition to either MMF or cyclophosphamide with or without eculizumab.<xref ref-type="bibr" rid="article-169701.r2">[2]</xref><xref ref-type="bibr" rid="article-169701.r15">[15]</xref></p>
        <p>The VALIANT trial is a phase III trial evaluating the use of pegcetacoplan on C3 glomerulopathy. Preliminary data shows that pegcetacoplan, a C3/C3b inhibitor, is effective in reducing proteinuria in this condition.<xref ref-type="bibr" rid="article-169701.r16">[16]</xref> The APPEAR-C3G trial is another phase III trial evaluating the effect of iptacopan on C3G in patients with biopsy-proven disease, including transplant patients. Iptacopan is an orally administered Factor B inhibitor that prevents the formation of C3 convertase, thereby inhibiting the alternative complement pathway. Currently used for paroxysmal nocturnal hemoglobinuria, it has also been tested for C3G and found to be effective in reducing C3 deposits in the disease.<xref ref-type="bibr" rid="article-169701.r17">[17]</xref><xref ref-type="bibr" rid="article-169701.r18">[18]</xref> Avacopan, a C5a receptor antagonist, is used as adjunctive therapy for ANCA-associated vasculitis. A randomized control trial showed no improvement in proteinuria or disease activity index when compared to placebo when used for C3G.<xref ref-type="bibr" rid="article-169701.r19">[19]</xref> Plasma therapy and plasma exchange have also not yet proven effective, likely due to the reaccumulation of autoantibodies.<xref ref-type="bibr" rid="article-169701.r2">[2]</xref></p>
        <p>Patients who fail to respond to therapies are encouraged to enroll in clinical trials. Novel emerging therapies targeting various regulators of complement activation are being investigated in phase 2 and 3 clinical trials.<xref ref-type="bibr" rid="article-169701.r5">[5]</xref> Some other agents studied have included danicopan, gene therapy, and stem cell treatment, but none of these have been proven effective at this time.<xref ref-type="bibr" rid="article-169701.r5">[5]</xref><xref ref-type="bibr" rid="article-169701.r20">[20]</xref><xref ref-type="bibr" rid="article-169701.r19">[19]</xref><xref ref-type="bibr" rid="article-169701.r21">[21]</xref></p>
      </sec>
      <sec id="article-169701.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Diagnosis of C3G must include consideration of immune complex glomerulonephritis and infection-related glomerulonephritis (IRGN) in the differential diagnosis. Immunofluorescence studies on formalin-fixed, paraffin-embedded tissue can sometimes fail to detect immune complex glomerulonephritis, potentially leading to a misdiagnosis of C3G. This occurs because formalin can &#x0201c;mask&#x0201d; tissue antigens, interfering with their interaction with immunoglobulins and diminish their staining intensity. Immunofluorescence techniques such as using pronase, which helps &#x0201c;unmask&#x0201d; these antigens, have been developed to mitigate such diagnostic challenges.<xref ref-type="bibr" rid="article-169701.r22">[22]</xref> In addition, using frozen tissue rather than formalin or paraffin-fixed tissue may be more accurate.<xref ref-type="bibr" rid="article-169701.r2">[2]</xref></p>
        <p>In the case of IRGN, it is important to remember that C3-dominant immunofluorescence findings may represent late stages of IRGN, making it difficult to distinguish from C3G, warranting consideration in the differential diagnosis. The presence of subepithelial hump-shaped deposits commonly seen in IRGN&#x000a0;is also a feature of C3G and insufficient to distinguish IRGN&#x000a0;from C3G. The current consensus recommends monitoring these patients clinically and with laboratory tests. Patients with IRGN are expected to recover kidney function and resolve hypocomplementemia, proteinuria, and hematuria within 12 weeks.<xref ref-type="bibr" rid="article-169701.r3">[3]</xref> If clinical and laboratory abnormalities persist beyond 12 weeks, C3G should be suspected, and a kidney biopsy should be performed to help differentiate between these 2 conditions.</p>
      </sec>
      <sec id="article-169701.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Progression to&#x000a0;end-stage kidney disease (ESKD) in cases of C3G occurs in up to 70% of children and 30% to 50% of adults within 10 years. In addition, the disease recurs in renal transplants and is responsible for graft loss in about 50% of cases.<xref ref-type="bibr" rid="article-169701.r2">[2]</xref>&#x000a0;Up to 50% of patients progress to ESKD in 5 years.<xref ref-type="bibr" rid="article-169701.r3">[3]</xref><xref ref-type="bibr" rid="article-169701.r11">[11]</xref> Multiple study results have identified clinical and histologic features associated with increased risk of progression. Features associated with a high risk of progression to ESKD include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Low baseline estimated glomerular filtration rate</p>
          </list-item>
          <list-item>
            <p>High level of proteinuria at baseline</p>
          </list-item>
          <list-item>
            <p>High chronicity score on biopsy</p>
          </list-item>
          <list-item>
            <p>Absence of immunosuppression therapy</p>
          </list-item>
          <list-item>
            <p>High stabilizing capacity of C3 nephritic factor&#x000a0;<xref ref-type="bibr" rid="article-169701.r3">[3]</xref><xref ref-type="bibr" rid="article-169701.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>In patients with ESKD secondary to C3G who receive a kidney transplant, the disease recurs in more than 50% of patients, often within the first year.<xref ref-type="bibr" rid="article-169701.r23">[23]</xref> Disease recurrence is more frequent in DDD than in C3GN (80% vs 70%, respectively).<xref ref-type="bibr" rid="article-169701.r23">[23]</xref></p>
      </sec>
      <sec id="article-169701.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications from C3G depend on the severity of the disease at presentation and its progression. Complications include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Risk of progression to chronic kidney disease and ESKD</p>
          </list-item>
          <list-item>
            <p>Complications of chronic kidney disease and ESKD: hypertension, increased cardiovascular risk, anemia, mineral bone disease</p>
          </list-item>
          <list-item>
            <p>Risk of nephrotic syndrome: dyslipidemia, volume overload, hypercoagulable state</p>
          </list-item>
          <list-item>
            <p>Complications and toxicity from immunosuppressive therapy</p>
          </list-item>
          <list-item>
            <p>Risk of opportunistic infections</p>
          </list-item>
          <list-item>
            <p>Risk of malignancy or infertility from cyclophosphamide</p>
          </list-item>
          <list-item>
            <p>Risk of steroid toxicity, including gastrointestinal, bone disease, glucose intolerance, volume overload, and hypertension</p>
          </list-item>
          <list-item>
            <p>Calcineurin inhibitor toxicity, including nephrotoxicity and neurotoxicity</p>
          </list-item>
          <list-item>
            <p>Mycophenolate mofetil side effects, including gastrointestinal, bone marrow suppression, teratogenicity</p>
          </list-item>
          <list-item>
            <p>Recurrence of disease post-transplant and subsequent burden of ESKD and dialysis-dependence</p>
          </list-item>
          <list-item>
            <p>Retinal complications in DDD, eg, drusen development</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-169701.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education is essential in managing C3G effectively. Patients should be educated about the importance of regularly monitoring kidney function, blood pressure, and proteinuria to detect disease progression early. Education on recognizing signs and symptoms of potential complications, such as fatigue, edema, and uncontrolled hypertension, is essential. Patients should also be advised on the importance of adhering to prescribed treatments, including immunosuppressive therapy and complement inhibitors, to control the disease and prevent relapses.</p>
        <p>Lifestyle modifications should be emphasized, such as maintaining a low-sodium diet, avoiding non-steroidal anti-inflammatory drugs, and managing cardiovascular risk factors. Since genetic factors can play a role in C3 glomerulopathy, discussing the possibility of genetic counseling and family screening may benefit some patients. By empowering patients with knowledge about their condition, healthcare professionals can help improve adherence to treatment plans, enhance patient outcomes, and reduce the risk of long-term kidney damage.</p>
      </sec>
      <sec id="article-169701.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Improving outcomes for patients with C3G requires a coordinated effort from a multidisciplinary healthcare team. Nephrologists lead the diagnosis and management of the disease, with support from pathologists who provide critical biopsy interpretations. Genetic counselors can offer insights into hereditary risks and guide testing, while pharmacists play a key role in managing complex medication regimens and ensuring patient safety.</p>
        <p>Nurses and nurse practitioners are vital for educating patients, monitoring treatment adherence, and managing side effects. Primary care clinicians and specialists help manage comorbid conditions impacting disease progression. Effective communication and regular case discussions among team members are essential for delivering comprehensive, patient-centered care, ultimately enhancing clinical outcomes and patient quality of life.</p>
      </sec>
      <sec id="article-169701.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=169701&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=169701">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/169701/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=169701">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-169701.s15">
        <title>References</title>
        <ref id="article-169701.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schena</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rossini</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease.</article-title>
            <source>Int J Mol Sci</source>
            <year>2020</year>
            <month>Jan</month>
            <day>14</day>
            <volume>21</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">31947692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>RJH</given-names>
              </name>
              <name>
                <surname>Appel</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Blom</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>D'Agati</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Fakhouri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fremeaux-Bacchi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>J&#x000f3;zsi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kavanagh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lambris</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Noris</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pickering</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Remuzzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de C&#x000f3;rdoba</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Van der Vlag</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zipfel</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Nester</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>C3 glomerulopathy - understanding a rare complement-driven renal disease.</article-title>
            <source>Nat Rev Nephrol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>129</fpage>
            <page-range>129-143</page-range>
            <pub-id pub-id-type="pmid">30692664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wooden</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nester</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Bomback</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Update on C3 Glomerulopathy.</article-title>
            <source>Adv Kidney Dis Health</source>
            <year>2024</year>
            <month>May</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>223</fpage>
            <page-range>223-233</page-range>
            <pub-id pub-id-type="pmid">39004462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ponticelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Calatroni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moroni</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>C3 glomerulopathies: dense deposit disease and C3 glomerulonephritis.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2023</year>
            <volume>10</volume>
            <fpage>1289812</fpage>
            <pub-id pub-id-type="pmid">38076230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tarragon Estebanez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bomback</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>C3 Glomerulopathy: Novel Treatment Paradigms.</article-title>
            <source>Kidney Int Rep</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>569</fpage>
            <page-range>569-579</page-range>
            <pub-id pub-id-type="pmid">38481517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmad</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Bomback</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>C3 Glomerulopathy: Pathogenesis and Treatment.</article-title>
            <source>Adv Chronic Kidney Dis</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>104</fpage>
            <page-range>104-110</page-range>
            <pub-id pub-id-type="pmid">32553242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ravindran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RJH</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>C3 glomerulopathy associated with monoclonal Ig&#x000a0;is a distinct subtype.</article-title>
            <source>Kidney Int</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>94</volume>
            <issue>1</issue>
            <fpage>178</fpage>
            <page-range>178-186</page-range>
            <pub-id pub-id-type="pmid">29729982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barbour</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Pickering</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Terence Cook</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Dense deposit disease and C3 glomerulopathy.</article-title>
            <source>Semin Nephrol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>493</fpage>
            <page-range>493-507</page-range>
            <pub-id pub-id-type="pmid">24161036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ravindran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RJH</given-names>
              </name>
              <name>
                <surname>De Vriese</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>93</volume>
            <issue>8</issue>
            <fpage>991</fpage>
            <page-range>991-1008</page-range>
            <pub-id pub-id-type="pmid">30077216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Palma</surname>
                <given-names>LMP</given-names>
              </name>
              <name>
                <surname>Theis</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
            </person-group>
            <article-title>Proteomic Analysis of Complement Proteins in Glomerular Diseases.</article-title>
            <source>Kidney Int Rep</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>827</fpage>
            <page-range>827-836</page-range>
            <pub-id pub-id-type="pmid">37069992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caravaca-Font&#x000e1;n</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Trujillo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az-Encarnaci&#x000f3;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cabello</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ariceta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Quintana</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Marco</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Barros</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Mendiola</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Ju&#x000e1;rez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de la Cerda</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez de Jos&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez G&#x000f3;mez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>&#x000c1;vila</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bravo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lumbreras</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Allende</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sanchez de la Nieta</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Olea</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Melgosa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huerta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miquel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fraga</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Lorenzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Draibe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shabaka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Illescas</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Calvo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oviedo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Da Silva</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Goicoechea de Jorge</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Caravaca</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Praga</surname>
                <given-names>M</given-names>
              </name>
              <collab>C3G Study Group of the Spanish Group for the Study of Glomerular Diseases (GLOSEN)</collab>
            </person-group>
            <article-title>Validation of a Histologic Scoring Index for C3 Glomerulopathy.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2021</year>
            <month>May</month>
            <volume>77</volume>
            <issue>5</issue>
            <fpage>684</fpage>
            <page-range>684-695.e1</page-range>
            <pub-id pub-id-type="pmid">33359150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chabannes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rabant</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>El Sissy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dragon-Durey</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vieira Martins</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Meuleman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Karras</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buob</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bridoux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Daugas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Audard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Caillard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Olagne</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kandel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ferlicot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Philipponnet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Crepin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Thervet</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ducloux</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fr&#x000e9;meaux-Bacchi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chauvet</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>C3 Glomerulopathy With Concurrent Thrombotic Microangiopathy: Clinical and Immunological Features.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>82</volume>
            <issue>3</issue>
            <fpage>279</fpage>
            <page-range>279-289</page-range>
            <pub-id pub-id-type="pmid">37061020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rovin</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Adler</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Barratt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bridoux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Burdge</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Glassock</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>DRW</given-names>
              </name>
              <name>
                <surname>Jha</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Liew</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Mej&#x000ed;a-Vilet</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Nester</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rave</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Ronco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>SCW</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vivarelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wetzels</surname>
                <given-names>JFM</given-names>
              </name>
              <name>
                <surname>Lytvyn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Tunnicliffe</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Howell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tonelli</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Earley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.</article-title>
            <source>Kidney Int</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>100</volume>
            <issue>4</issue>
            <fpage>753</fpage>
            <page-range>753-779</page-range>
            <pub-id pub-id-type="pmid">34556300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caravaca-Font&#x000e1;n</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az-Encarnaci&#x000f3;n</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lucientes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cavero</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cabello</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ariceta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Quintana</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Marco</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Barros</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Mendiola</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Ju&#x000e1;rez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez de Jos&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rabasco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rodado</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez G&#x000f3;mez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>&#x000c1;vila</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Bravo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lumbreras</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Allende</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sanchez de la Nieta</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Olea</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Melgosa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huerta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miquel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fraga</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Lorenzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Draibe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cano-Meg&#x000ed;as</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shabaka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Rubio</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Fenollosa</surname>
                <given-names>M&#x000c1;</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-Penagos</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Da Silva</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Alonso Titos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez de C&#x000f3;rdoba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goicoechea de Jorge</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Praga</surname>
                <given-names>M</given-names>
              </name>
              <collab>Spanish Group for the Study of Glomerular Diseases GLOSEN</collab>
            </person-group>
            <article-title>Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2020</year>
            <month>Sep</month>
            <day>07</day>
            <volume>15</volume>
            <issue>9</issue>
            <fpage>1287</fpage>
            <page-range>1287-1298</page-range>
            <pub-id pub-id-type="pmid">32816888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pickering</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>D'Agati</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Nester</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Appel</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Alpers</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Bajema</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Bedrosian</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fakhouri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Fogo</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Fr&#x000e9;meaux-Bacchi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gale</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Goicoechea de Jorge</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Holers</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lavin</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Medjeral-Thomas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Paul Morgan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nast</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Noel</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez de C&#x000f3;rdoba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Servais</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Tamburini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thurman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Zavros</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>HT</given-names>
              </name>
            </person-group>
            <article-title>C3 glomerulopathy: consensus report.</article-title>
            <source>Kidney Int</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>84</volume>
            <issue>6</issue>
            <fpage>1079</fpage>
            <page-range>1079-89</page-range>
            <pub-id pub-id-type="pmid">24172683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dixon</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Greenbaum</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rajan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases.</article-title>
            <source>Kidney Int Rep</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>8</volume>
            <issue>11</issue>
            <fpage>2284</fpage>
            <page-range>2284-2293</page-range>
            <pub-id pub-id-type="pmid">38025230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nester</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cavero</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Karras</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Le Quintrec</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lightstone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Eisenberger</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Soler</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kavanagh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Daina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Praga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Medjeral-Thomas</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>G&#x000e4;ckler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garcia-Carro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Biondani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chaperon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kulmatycki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Milojevic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>NJA</given-names>
              </name>
              <name>
                <surname>Nidamarthy</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Junge</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Remuzzi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.</article-title>
            <source>Kidney Int Rep</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>2754</fpage>
            <page-range>2754-2764</page-range>
            <pub-id pub-id-type="pmid">38106570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bomback</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Kavanagh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vivarelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>NJA</given-names>
              </name>
              <name>
                <surname>Trapani</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RJH</given-names>
              </name>
            </person-group>
            <article-title>Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial.</article-title>
            <source>Kidney Int Rep</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>7</volume>
            <issue>10</issue>
            <fpage>2150</fpage>
            <page-range>2150-2159</page-range>
            <pub-id pub-id-type="pmid">36217526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bomback</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Herlitz</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Kedia</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yue</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lafayette</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Safety and Efficacy of Avacopan in Patients with C3 Glomerulopathy: Randomized, Double-Blind Clinical Trial.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2024</year>
            <month>Oct</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">39392695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montenegro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Giannuzzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Picerno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cicirelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stea</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Di Leo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sallustio</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>How Stem and Progenitor Cells Can Affect Renal Diseases.</article-title>
            <source>Cells</source>
            <year>2024</year>
            <month>Aug</month>
            <day>30</day>
            <volume>13</volume>
            <issue>17</issue>
            <pub-id pub-id-type="pmid">39273032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chew</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Grigsby</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hester</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Amason</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McPherson</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Visel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Flannery</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Rickman</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Truncated Complement Factor H Y402 Gene Therapy Cures C3 Glomerulonephritis.</article-title>
            <source>bioRxiv</source>
            <year>2024</year>
            <month>Sep</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">39345485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Das</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lakadong</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Dey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Raphael</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>A Comparative Study of Immunofluorescence on Formalin-Fixed, Paraffin-Embedded Versus Fresh Frozen Kidney Biopsy.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>e40978</fpage>
            <pub-id pub-id-type="pmid">37503479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-169701.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartoli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dello Strologo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grandaliano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pesce</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Updates on C3 Glomerulopathy in Kidney Transplantation: Pathogenesis and Treatment Options.</article-title>
            <source>Int J Mol Sci</source>
            <year>2024</year>
            <month>Jun</month>
            <day>13</day>
            <volume>25</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">38928213</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
